Lv3
240 积分 2025-03-03 加入
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
8个月前
已完结
Radiologic–Pathologic Correlation of Hepatocellular Carcinoma Treated with Chemoembolization
8个月前
已完结
Drug-eluting beads TACE is safe and non-inferior to conventional TACE in HCC patients with TIPS
9个月前
已完结
Identifying optimal candidates for post-TIPS patients with HCC undergoing TACE: a multicenter observational study
9个月前
已完结
Surgical Site Infections, Risk Factors, and Outcomes After Liver Transplant
9个月前
已完结
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study
10个月前
已完结
Anthropometric indicators of adiposity and risk of primary liver cancer: A systematic review and dose–response meta-analysis
10个月前
已完结
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
11个月前
已完结
皖公网安备34019202002308
